Super-enhancers: A new frontier for glioma treatment

Cheng, Meng; Zhang, Zheng Wei; Ji, Xing; Xu, Yadi; Bian, Erbao; Zhao, Bing

doi:10.1016/j.bbcan.2020.188353

Cited by 26 publications

(21 citation statements)

References 181 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 And high-grade gliomas, which account for more than 50% of all gliomas, have been considered as a major threat to human health. 2 Nowadays, despite great advances in therapeutic interventions, such as surgical resection, oral alkylating agents, and radiation, the prognosis in glioma patients remains poor. 3 , 4 Therefore, exploring the underlying molecular mechanisms of glioma development is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: MYC-mediated upregulation of PNO1 promotes glioma tumorigenesis by activating THBS1/FAK/Akt signaling

et al. 2021

View full text Add to dashboard Cite

PNO1 has been reported to be involved in tumorigenesis, however, its role in glioma remains unexplored. In the present study, PNO1 expression in glioma from on-line databases, cDNA, and tissue microarrays was upregulated and associated with poor prognosis. PNO1 knockdown inhibits tumor cell growth and invasion both in vitro and in vivo; whereas PNO1 overexpression promoted cell proliferation and invasion in vitro. Notably, PNO1 interacted with THBS1 and the promotion of glioma by PNO1 overexpression could be attenuated or even reversed by simultaneously silencing THBS1. Functionally, PNO1 was involved in activation of FAK/Akt pathway. Moreover, overexpressing MYC increased PNO1 promoter activity. MYC knockdown decreased PNO1 and THBS1 expression, while inhibited cell proliferation and invasion. In conclusion, MYC-mediated upregulation of PNO1 contributes to glioma progression by activating THBS1/FAK/Akt signaling. PNO1 was reported to be a tumor promotor in the development and progression of glioma and may act as a candidate of therapeutic target in glioma treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: MYC-mediated upregulation of PNO1 promotes glioma tumorigenesis by activating THBS1/FAK/Akt signaling

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Human brain glioma is the most common primary malignant tumor. But the prognosis for patients with these tumors remains poor despite standard care of surgery, radiation therapy and temozolomide chemotherapy [ 19 ]. Therefore, it is imperative to identify potential prognostic and therapeutic targets for glioma.…”

Section: Discussionmentioning

confidence: 99%

Identification of a mesenchymal-related signature associated with clinical prognosis in glioma

Zhang

Chen

Huo

et al. 2021

Aging

Self Cite

View full text Add to dashboard Cite

Malignant glioma with a mesenchymal (MES) signature is characterized by shorter survival time due to aggressive dissemination and resistance to chemoradiotherapy. Here, this study used the TCGA database as the training set and the CGGA database as the testing set. Consensus clustering was performed on the two data sets, and it was found that two groups had distinguished prognostic and molecular features. Cox analysis and Lasso regression analysis were used to construct MES signature-based risk score model of glioma. Our results show that MES signature-based risk score model can be used to assess the prognosis of glioma. Three methods (ROC curve analyses, univariate Cox regression analysis, multivariate Cox regression analysis) were used to investigate the prognostic role of texture parameters. The result showed that the MES-related gene signature was proved to be an independent prognostic factor for glioma. Furthermore, functional analysis of the gene related to the risk signature showed that the genes sets were closely related to the malignant process of tumors. Finally, FCGR2A and EHD2 were selected for functional verification. Silencing these two genes inhibited the proliferation, migration and invasion of gliomas and reduced the expression of mesenchymal marker genes. Collectively, MES-related risk signature seems to provide a novel target for predicting the prognosis and treatment of glioma.

show abstract

“…Glioma is the most common primary malignant tumor of the central nervous system. Moreover, glioma has a high recurrence rate, high mortality rate, and low cure rate (1). The World Health Organization (WHO) classifies glioma cells into four types according to their morphological characteristics and prognosis (2).…”

Section: Introductionmentioning

confidence: 99%

A Signature of Nine lncRNA Methylated Genes Predicts Survival in Patients With Glioma

et al. 2021

Self Cite

View full text Add to dashboard Cite

Glioma is one of the most common malignant tumors of the central nervous system, and its prognosis is extremely poor. Aberrant methylation of lncRNA promoter region is significantly associated with the prognosis of glioma patients. In this study, we investigated the potential impact of methylation of lncRNA promoter region in glioma patients to establish a signature of nine lncRNA methylated genes for determining glioma patient prognosis. Methylation data and clinical follow-up data were obtained from The Cancer Genome Atlas (TCGA). The multistep screening strategy identified nine lncRNA methylated genes that were significantly associated with the overall survival (OS) of glioma patients. Subsequently, we constructed a risk signature that containing nine lncRNA methylated genes. The risk signature successfully divided the glioma patients into high-risk and low-risk groups. Compared with the low-risk group, the high-risk group had a worse prognosis, higher glioma grade, and older age. Furthermore, we identified two lncRNAs termed PCBP1-AS1 and LINC02875 that may be involved in the malignant progression of glioma cells by using the TCGA database. Loss-of-function assays confirmed that knockdown of PCBP1-AS1 and LINC02875 inhibited the proliferation, migration, and invasion of glioma cells. Therefore, the nine lncRNA methylated genes signature may provide a novel predictor and therapeutic target for glioma patients.

show abstract

Super-enhancers: A new frontier for glioma treatment

Cited by 26 publications

References 181 publications

RETRACTED ARTICLE: MYC-mediated upregulation of PNO1 promotes glioma tumorigenesis by activating THBS1/FAK/Akt signaling

RETRACTED ARTICLE: MYC-mediated upregulation of PNO1 promotes glioma tumorigenesis by activating THBS1/FAK/Akt signaling

Identification of a mesenchymal-related signature associated with clinical prognosis in glioma

A Signature of Nine lncRNA Methylated Genes Predicts Survival in Patients With Glioma

Contact Info

Product

Resources

About